Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

[11] Monnet DL(2020)RESTORE-IMI 1: A Multicenter, Randomized, Double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections Clin Infect Dis 70 1799-e4548

[12] Yahav D(2021)A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study) Clin Infect Dis 73 e4539-3048

[13] Giske CG(2016)MultiQC: summarize analysis results for multiple tools and samples in a single report Bioinformatics 32 3047-477

[14] Gramatniece A(2012)SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing J Comput Biol 19 455-1150

[15] Abodakpi H(2019)In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016 Eur J Clin Microbiol Infect Dis 38 1143-1510

[16] Tam VH(2021)Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales J Antimicrob Chemother 76 1498-14

[17] Leibovici L(2019)In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa BMC Microbiol 19 1-1771

[18] Navon-Venezia S(2009)Extended-spectrum cephalosporinases in Pseudomonas aeruginosa Antimicrob Agents Chemother 53 1766-1855

[19] Kondratyeva K(2006)Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product J Bacteriol 188 1847-3321

[20] Carattoli A(2009)Role of MexZ and PA5471 in transcriptional regulation of mexXY in Pseudomonas aeruginosa Microbiology 155 3312-2978

[11] Monnet DL(2020)RESTORE-IMI 1: A Multicenter, Randomized, Double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections Clin Infect Dis 70 1799-e4548

[12] Yahav D(2021)A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study) Clin Infect Dis 73 e4539-3048

[13] Giske CG(2016)MultiQC: summarize analysis results for multiple tools and samples in a single report Bioinformatics 32 3047-477

[14] Gramatniece A(2012)SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing J Comput Biol 19 455-1150

[15] Abodakpi H(2019)In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016 Eur J Clin Microbiol Infect Dis 38 1143-1510

[16] Tam VH(2021)Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales J Antimicrob Chemother 76 1498-14

[17] Leibovici L(2019)In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa BMC Microbiol 19 1-1771

[18] Navon-Venezia S(2009)Extended-spectrum cephalosporinases in Pseudomonas aeruginosa Antimicrob Agents Chemother 53 1766-1855

[19] Kondratyeva K(2006)Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product J Bacteriol 188 1847-3321

[20] Carattoli A(2009)Role of MexZ and PA5471 in transcriptional regulation of mexXY in Pseudomonas aeruginosa Microbiology 155 3312-2978